ProQR Therapeutics N.V. (NASDAQ:PRQR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The firm currently has a $6.00 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would indicate a potential downside of 0.83% from the company’s previous close.

According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

Other equities analysts have also issued research reports about the stock. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of ProQR Therapeutics N.V. in a research report on Tuesday, June 20th. ValuEngine upgraded shares of ProQR Therapeutics N.V. from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $14.30.

ProQR Therapeutics N.V. (PRQR) traded up 1.68% during mid-day trading on Wednesday, hitting $6.05. 140,634 shares of the stock traded hands. The stock has a 50-day moving average of $5.11 and a 200 day moving average of $4.97. The firm’s market cap is $145.84 million. ProQR Therapeutics N.V. has a 1-year low of $3.65 and a 1-year high of $8.70.

TRADEMARK VIOLATION WARNING: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/17/proqr-therapeutics-n-v-prqr-raised-to-buy-at-zacks-investment-research.html.

A number of hedge funds have recently bought and sold shares of the business. Redmile Group LLC lifted its stake in ProQR Therapeutics N.V. by 2.8% during the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after buying an additional 43,050 shares in the last quarter. Artal Group S.A. lifted its stake in ProQR Therapeutics N.V. by 25.0% during the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after buying an additional 100,000 shares in the last quarter. Sphera Funds Management LTD. lifted its stake in ProQR Therapeutics N.V. by 65.0% during the first quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock valued at $1,650,000 after buying an additional 130,000 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in ProQR Therapeutics N.V. during the second quarter valued at about $2,028,000. 35.93% of the stock is owned by institutional investors.

About ProQR Therapeutics N.V.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Get a free copy of the Zacks research report on ProQR Therapeutics N.V. (PRQR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.